<div id="readability-page-1"><p><span>Abivax (NASDAQ:ABVX - Get Free Report)</span> was upgraded by research analysts at Wall Street Zen from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note issued on Saturday.</p><p>Several other research firms have also recently commented on ABVX. Citigroup  restated a &#34;market outperform&#34; rating on shares of Abivax in a research report on Thursday, January 8th. Morgan Stanley boosted their price target on Abivax from $101.00 to $145.00 and gave the stock an &#34;overweight&#34; rating in a research report on Friday, January 9th. Oppenheimer  set a $131.00 price target on Abivax in a report on Thursday, January 8th. Jefferies Financial Group started coverage on shares of Abivax in a research note on Monday, March 16th. They set a &#34;buy&#34; rating and a $160.00 price objective on the stock. Finally, Weiss Ratings  reaffirmed a &#34;sell (d-)&#34; rating on shares of Abivax in a report on Wednesday, January 21st. One analyst  has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one  has issued  a Sell rating to the company's stock. Based on data from MarketBeat.com, Abivax  has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $137.15.</p><p><b>View Our Latest Stock Report on Abivax</b></p><h2>Abivax Stock Down 1.9%</h2><p>Shares of NASDAQ:ABVX opened at $120.16 on Friday. The company's 50-day moving average price is $119.10 and its 200 day moving average price is $114.65. The company has a market cap of $9.53 billion, a PE ratio of -22.38 and a beta of 1.68. Abivax has a fifty-two week low of $5.59 and a fifty-two week high of $148.83. </p><p>Abivax (NASDAQ:ABVX - Get Free Report) last announced its quarterly earnings results on Saturday, February 14th. The company reported ($1.20) EPS for the quarter. The business had revenue of $0.52 million for the quarter.  As a group, equities analysts anticipate that  Abivax will post -2.83 EPS for the current year. </p><h2>Hedge Funds Weigh In On Abivax</h2><p>Several hedge funds have recently modified their holdings of ABVX. WPG Advisers LLC lifted its holdings in shares of  Abivax by 125.9% in the fourth quarter. WPG Advisers LLC now owns 454 shares of the company's stock valued at $61,000 after buying an additional 253 shares during the period.  Caitong International Asset Management Co. Ltd grew its holdings in  Abivax by 661.5% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 396 shares of the company's stock worth $53,000 after acquiring an additional 344 shares during the period.  EverSource Wealth Advisors LLC grew its holdings in  Abivax by 4,612.5% during the third quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company's stock worth $32,000 after acquiring an additional 369 shares during the period.  First Horizon Corp bought a new stake in  Abivax in the third quarter worth about $36,000.  Finally, Bank of Hawaii raised its position in  Abivax by 14.9% in the fourth quarter. Bank of Hawaii now owns 3,454 shares of the company's stock worth $466,000 after acquiring an additional 448 shares in the last quarter. 47.91% of the stock is currently owned by institutional investors and hedge funds. </p><h2>About Abivax</h2> (Get Free Report)<p>Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles. </p><p>Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.</p><h2>See Also</h2><ul><li>Five stocks we like better than Abivax</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJWWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJWWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Abivax Right Now?</h2><p>Before you consider Abivax, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abivax wasn't on the list.</p><p>While Abivax currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ABVX

<p>Wall Street Zen upgraded Abivax (NASDAQ:ABVX) from a "sell" to a "hold" rating. Other firms like Citigroup and Morgan Stanley have also provided positive ratings, with Morgan Stanley raising the price target to $145. Abivax's stock is currently down 1.9%, trading at $120.16, with a market cap of $9.53 billion. The company reported a quarterly EPS of ($1.20) and anticipates a -2.83 EPS for the current year. Institutional investors hold 47.91% of the stock.</p>

Market Beat

Abivax SA

Citigroup

Morgan Stanley

Oppenheimer

Jefferies Financial

First Horizon

Bank of Hawaii

CITIGROUP INC 6.250 NON CUM SER II PFD WI

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

FIRST HORIZON CORPORATION 6.50% DEP SHS REP 1/4000 PER PFD SER E

FIRST HORIZON CORPORATION DEP SHS REP 1/400 NON CUM PER PFD SER C

FIRST HORIZON CORPORATION DEP SHS REP 1/400 NON CUM PER PFD SER B

FIRST HORIZON CORPORATION DEP SH REP 1/4000 INT NON CUM PFD H WI

FIRST HORIZON CORPORATION DEP SHS REPSTG 1/4000TH PERP PFD SER F

BANK OF HAWAII CORPORATION DEP SHS REPSTG 1/40TH INT SH NON CUM PER

BANK OF HAWAII CORP 4.375% DEP SHS REPSTG 1/40TH PFD SER A

Abivax (NASDAQ:ABVX) Upgraded to "Hold" at Wall Street Zen